ExodusPoint Capital Management’s Ginkgo Bioworks DNA Stock Holding History

ExodusPoint Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$148K	Sell	14,969 -50,794	-77%	-$425K	﹤0.01%	1443
2026 Q1	$403K	Buy	+65,763	New	+$547K	﹤0.01%	1246
2024 Q3	–	Sell	-3,601	Closed	-$48K	–	1722
2024 Q2	$48K	Buy	+3,601	New	+$107K	﹤0.01%	1449
2023 Q3	–	Sell	-703	Closed	-$52K	–	1791
2023 Q2	$52K	Sell	703 -20,421	-97%	-$1.21M	﹤0.01%	1774
2023 Q1	$1.12M	Buy	+21,124	New	+$1.34M	0.01%	1104
2022 Q3	–	Sell	-7,099	Closed	-$676K	–	1968
2022 Q2	$676K	Sell	7,099 -12,176	-63%	-$1.49M	0.01%	1248
2022 Q1	$3.11M	Buy	19,275 +17,935	+1,338%	+$3.49M	0.04%	578
2021 Q4	$445K	Buy	+1,340	New	+$637K	﹤0.01%	1482

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

ExodusPoint Capital Management's DNA Position: Q2 2026 in Review

ExodusPoint Capital Management reduced its Ginkgo Bioworks (DNA) stake by 77% in Q2 2026, selling an estimated $425K and leaving 14,969 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #1443.

ExodusPoint Capital Management first reported a position in DNA in Q4 2021 and has held it in 8 quarters since. The position peaked at $3.11M in Q1 2022. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

ExodusPoint Capital Management held 14,969 shares of Ginkgo Bioworks worth $148K as of Q2 2026.
ExodusPoint Capital Management sold 50,794 Ginkgo Bioworks shares in Q2 2026, an estimated $425K.
Ginkgo Bioworks made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q2 2026, its #1443 holding.
ExodusPoint Capital Management first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 8 quarters since.
ExodusPoint Capital Management's Ginkgo Bioworks position peaked at $3.11M in Q1 2022.
183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.